You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》麥格理升藥明生物(02269.HK)目標價至209.21元 受惠內地生物製劑銷售增長
阿思達克 09-17 14:31
麥格理發表研究報告指,分析全球合同生產服務(CDMO/CMO)的挑戰性增加,因市場非常分散(前五位的公司市場佔比不足15%),雖然藥明生物(02269.HK)排名第三,全球佔比5%,中國佔比79%,仍有巨大潛力。

市場調查分析預期,中國的生物製藥市場在未來3年複合增長18%,而公司來自中國的收入增長應與市場相符,故中國市場會是公司短期重要增長動力。而北美市場目前具不確定性,增長由去年的66.5%降至今年上半年的3.7%,而市場增長亦只有少於10%。

該行將公司目標價由153.56元升至209.21元,重申「跑贏大市」評級。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account